Detalhe da pesquisa
1.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737717
2.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31003911
3.
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Br J Cancer
; 118(6): 777-784, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438370
4.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(6): 654-e58, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438092
5.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275117
6.
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N Engl J Med
; 371(20): 1867-76, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25265494
7.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 17(9): 1248-60, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27480103
8.
Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
J Cardiovasc Pharmacol
; 61(1): 83-9, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23107871
9.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(10): 1281, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29018169
10.
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Br J Clin Pharmacol
; 74(5): 788-96, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22458643
11.
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
Open Forum Infect Dis
; 9(4): ofac053, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295819
12.
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
Open Forum Infect Dis
; 9(8): ofac406, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043180
13.
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Drug Metab Dispos
; 39(8): 1460-7, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21602311
14.
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Clin Pharmacol Drug Dev
; 10(2): 144-152, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696585
15.
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.
Clin Cancer Res
; 25(11): 3239-3246, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824584
16.
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.
JCO Precis Oncol
; 2: 1-17, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135117
17.
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.
JCO Precis Oncol
; 2: 1-18, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135126
18.
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
Clin Cancer Res
; 23(17): 5238-5245, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28536307
19.
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
J Clin Pharmacol
; 54(4): 368-74, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24374975
20.
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
Clin Cancer Res
; 18(23): 6509-18, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23032746